Orexigen(R) Therapeutics to Speak at Upcoming C...( SAN DIEGO May 8 /- Orexigen(R) Therap...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Date:5/8/2009
SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the following investor conferences:
Bank of America and Merrill Lynch 2009 Health Care Conference
Date: Tuesday, May 12, 2009
Time: 2:40 p.m. - 3:10 p.m. Eastern
Location: The New York Palace Hotel, New York
Speaker: Michael Narachi, Chief Executive Officer
Canaccord Adams Diabetes and Obesity Conference
Date: Tuesday, May 12, 2009
Time: 10:40 a.m. - 11:10 a.m. Eastern
Location: InterContinental The Barclay New York, New York
Speaker: Graham Cooper, Chief Financial Officer
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.
'/>"/>
| SOURCE Orexigen Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
11. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Post Your Comments:
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3China Biologic Products to Ring NASDAQ Opening Bell 2China Biologic Products to Ring NASDAQ Opening Bell 3Dendreon Appoints Hans Bishop as Chief Operating Officer 2
Other Biology Technology:FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 2FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 3FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 4FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 5Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors 2
Breaking Biology News(10 mins):IGC scientist receives prestigious EMBO installation grant 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2Pathological gambling may be successfully treated with medications for substance addiction 2Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference 12680 1AACR CEO Margaret Foti receives honorary M D from the University of San Pablo CEU 49286 1AACR CEO Margaret Foti receives honorary M D from the University of San Pablo CEU 49286 2AACR CEO Margaret Foti receives honorary M D from the University of San Pablo CEU 49286 3Imagenetix Inc Reports Year End Results 49281 1Imagenetix Inc Reports Year End Results 49281 2Imagenetix Inc Reports Year End Results 49281 3Imagenetix Inc Reports Year End Results 49281 4Imagenetix Inc Reports Year End Results 49281 5
Other Biology News:NIH grants Phylonix Phase II SBIR to develop high-throughput in vivo zebrafish assays 2Studies offer guide as protein interaction mapping comes of age 2Studies offer guide as protein interaction mapping comes of age 3Studies offer guide as protein interaction mapping comes of age 4Wonderful cheese is all in the culture 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |